Consumers have unfavorable views of drugmakers and health insurers: But these companies are simultaneously getting higher brand equity. Their growth is predicated on revenue-driving actions that consumers believe lead to high healthcare prices.

Trump admin invests $500M for universal vaccine project: Perhaps the administration isn’t as anti-vax as publicly perceived. However, vaccine makers are still on high alert as approval timelines for vaccines undergoing trials could get pushed back.

Vaccine integrity project launched to counter medical misinformation: Vaccine makers have the tough job of currying favor with Trump’s health administration, while preserving the public’s trust in their medicines.

Only 30% of healthcare and pharma AI pilots make it to production: AI companies must demonstrate tech prowess, address security concerns, and drive clinical or business outcomes to convert more pilots into full-scale implementation..

Pharma companies sidestepped the Trump administration's broad tariff orders: It’s a pharma win for tariffs, but the president’s comments on foreign tax breaks and manufacturing reshoring demands still signal potential for challenges ahead.

Consumers are turning to digital channels for medical information and advice and to research healthcare products, treatments, and services. Here’s what healthcare and pharma marketers need to know about converting information-seeking consumers into customers.

Consumers blame Insurers, pharma for the state of US healthcare: Both industries continue to face serious trust issues with consumers that marketing alone won’t fix.

President-elect Donald Trump's second term promises profound shifts across commerce, technology, and regulation that will reshape how businesses operate and consumers behave. As the president-elect prepares to take office, his policy priorities are already triggering market reactions and pivots from major corporations.

From the rise of sophisticated AI-driven tools to new policies reshaping data privacy and competition, 2025 promises to be a year of relentless change. Companies that adapt will thrive, while others risk being left behind in a swiftly moving market.

B2B digital ad spending is expected to rebound in 2024. Trends in B2B buying behavior, programmatic advertising, and AI use are contributing to the shift in spending toward display, mobile, social media, and video.

After an unexpectedly solid 2023, the good times will continue for ad spending in most US industry verticals in 2024. Telecom will lead in growth, and numerous categories will outpace their 2023 increases. A few unusual results are on tap as well.

Consumers are using the internet and social media to a great extent for healthcare purposes. Here’s what healthcare and pharma marketers need to know about how online-acquired information influences patient action.

The travel and retail industries will post healthy digital ad spending growth figures this year, but many other verticals we track will underperform compared with the national growth average. Next year is looking better for almost all of them.

B2B digital ad spending will continue to grow at a slower pace across key industries in 2023. More B2B buyers are millennials and Gen Zers, shifting ad buys from search to display, from Google to social media, and from desktop to mobile.

Pfizer expands its agreement with CytoReason by five years to boost AI’s role in drug development. We spotlight the trend in the pharma world.

Walgreens is helping its primary care partners reduce errors and speed up the reimbursement process as health execs plan to adopt RCM and billing tech.

After two years of dramatic highs and lows for various industries, digital ad spending growth rates will settle into relatively similar patterns for the 10 industries we track. However, aggregate spending will remain vastly different.

Amazon and CVS Caremark are among the top online pharmacies as consumers look to save time and money on their meds—which will outlast the period of economic uncertainty.

Amwell scored a CVS deal, should Teladoc worry?: We examine Amwell’s virtual care partnership with CVS amid its rosy Q2 earnings and posit what both mean for competitors.